#United States #New York #Gross Law Firm #Intellia Therapeutics #NTLA

Intellia Therapeutics Class Action Alert

The Gross Law Firm has officially notified shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) regarding an upcoming class action lawsuit that many investors may find relevant. As the deadline approaches on April 14, 2025, those who bought shares during a specific period should take note of their legal rights and options.

Background of the Case

The class action pertains primarily to shareholders who purchased Intellia stock between July 30, 2024, and January 8, 2025. The lawsuit alleges that during this timeframe, the company made misleading statements regarding its ongoing research on NTLA-3001, a treatment aimed at addressing lung disease associated with alpha-1 antitrypsin deficiency (AATD).

Key Allegations

According to the filed complaint, the defendants allegedly failed to disclose important information that would have influenced investor decisions. Specifically, they claimed certainty about Intellia's research timeline and the dosing schedule for NTLA-3001, stating the first patient would be treated in the second half of 2024. However, it later became evident that the demand for viral-based gene editing was waning, overshadowed by the growing popularity of non-viral methods recognized for their cost-effectiveness and efficiency.

The turning point came on January 9, 2025, when Intellia publicly shared restructuring announcements. It revealed that the company would cease its NTLA-3001 research and implement a 27% workforce reduction in 2025. This shift drastically changed the investment landscape and directly affected stock prices. Following this announcement, Intellia's share price plummeted from $12.02 to $10.20 within just two trading days.

Next Steps for Shareholders

As an investor who may have been affected, it is crucial to register your information without delay, as this will help in tracking the progress of the case. Those interested in being appointed as lead plaintiffs or who simply wish to participate need to confirm their involvement before the deadline of April 14, 2025. The Gross Law Firm will support them throughout this process and monitor the case on their behalf—at no cost.

What You Should Know

By registering as a shareholder, investors will gain access to a comprehensive portfolio monitoring service designed to provide updates about the ongoing litigation. This support aims to ensure that all stakeholders stay informed about developments in the case, allowing them to make educated decisions moving forward.

Why Choose Gross Law Firm?

The Gross Law Firm is a respected name in class action representation, dedicated to safeguarding investors from misleading corporate practices. Their objective is clear: ensure that every investor receives fair treatment and that companies are held accountable for any potential wrongdoing. The firm has substantial experience dealing with issues surrounding corporate transparency and ethical governance, all critical in navigating the complex landscape of financial securities.

If you are a shareholder of Intellia Therapeutics seeking to understand your rights amid this turbulence, consider reaching out to the Gross Law Firm. They offer seasoned legal expertise and a commitment to ensuring that all investors can recover losses incurred due to corporate misrepresentations and fraud mechanisms.

Contact Information

For further inquiries and registration details, investors can connect with the Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In conclusion, time is of the essence—take action to protect your investments and seek rightful recourse in this unfolding legal matter concerning Intellia Therapeutics.